Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Jpn J Pharmacol ; 72(4): 325-33, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9015741

RESUMO

Influence of cardiotonic agents on the prognosis of heart failure depends on the individual therapeutic agents, and favorable and unfavorable effects of these agents have been reported in clinical trials. We studied the effect of the cardiotonic agent denopamine on the life span of cardiomyopathic hamsters (BIO 14.6 strain) in the heart failure period. Non-treated hamsters started to die at 40 weeks of age, and their survival rate decreased to 23.8% at the age of 65 weeks. Hamsters treated with denopamine (400 ppm in diet) from 36 weeks of age did not die until the age of 52 weeks, except in cases of accidental death. The survival rate of this group at 65 weeks of age was about 40%. Survival rates of these 2 groups were significantly different (P < 0.05) when animals with accidental death were excluded. To elucidate the mechanism of the effect of denopamine, we performed several experiments after dietary treatment with denopamine for 4 to 6 weeks from 37 weeks of age. Denopamine treatment lowered plasma levels of noradrenaline and dopamine (P < 0.05), but affected neither the cardiac contractility nor the beta-adrenoceptor density. In summary, denopamine significantly decreases the mortality of cardiomyopathic hamsters. Its effect to lower the plasma catecholamine levels may be responsible for the beneficial effect of denopamine.


Assuntos
Agonistas de Receptores Adrenérgicos beta 1 , Agonistas Adrenérgicos beta/uso terapêutico , Cardiomiopatias/tratamento farmacológico , Etanolaminas/uso terapêutico , Animais , Pressão Sanguínea/efeitos dos fármacos , Cardiomiopatias/patologia , Catecolaminas/sangue , Cricetinae , Testes de Função Cardíaca , Frequência Cardíaca/efeitos dos fármacos , Expectativa de Vida , Masculino , Tamanho do Órgão/efeitos dos fármacos , Músculos Papilares/efeitos dos fármacos , Músculos Papilares/metabolismo , Taxa de Sobrevida
2.
Eur J Pharmacol ; 317(2-3): 401-6, 1996 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-8997627

RESUMO

The protective effect of l-cis-diltiazem, the stereoisomer of d-cis-diltiazem, was studied against the veratridine-induced hypercontracture of rat myocytes. Veratridine increased both [Na+]i and [Ca2+]i, but did not cause hypercontracture in the absence of extracellular Ca2+. Both l-cis-diltiazem (0.1-10 microM) and d-cis-diltiazem (10-30 microM) inhibited the hypercontracture and the increase in [Ca2+]i in a concentration-dependent manner. However, l-cis-diltiazem did not exert a negative inotropic effect in K+ (20 mM)-depolarized rat papillary muscles even at a dose of 10 microM. As seen in the case of tetrodotoxin, l-cis-diltiazem and d-cis-diltiazem also suppressed the increase in [Na+]i. The results show that l-cis-diltiazem prevents the veratridine-induced hypercontracture of myocytes by suppression of the [Ca2+]i increase. The attenuation of the [Ca2+]i increase by l-cis-diltiazem was not dependent on inhibition of Ca2+ channels, but was partly due to inhibition of excessive Na+ entry via veratridine-modified Na+ channels.


Assuntos
Bloqueadores dos Canais de Cálcio/farmacologia , Diltiazem/farmacologia , Contração Miocárdica/efeitos dos fármacos , Veratridina/farmacologia , Animais , Benzofuranos , Cálcio/metabolismo , Corantes Fluorescentes , Fura-2 , Coração/efeitos dos fármacos , Técnicas In Vitro , Masculino , Miocárdio/citologia , Miocárdio/metabolismo , Músculos Papilares/efeitos dos fármacos , Ácidos Ftálicos , Ratos , Ratos Sprague-Dawley , Sódio/metabolismo , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA